Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JPI-289 in Acute Ischemic Stroke
NCT03062397Phase 2Unknown
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Amelparib in ischemic stroke, sponsored by Jeil Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
Amelparib
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03062397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062397.